AutoGenomics

INFINITI® CYP450 2D6-BC Assay
Directional Package Insert (DPI)

For *In Vitro* Diagnostic Use

CE

FOR EXPORT ONLY

Manufactured by AutoGenomics, Inc.,1600 Faraday Avenue, Carlsbad, CA USA 92008

Authorized EU Agent: Medical Device Safety Service GmbH (MDSS)
Schiffgraben 41, 30175 Hannover, Germany

AutoGenomics

INTENDED USE

The INFINITI CYP450 2D6-BC Assay is an *in vitro* diagnostic test for the identification of a patient's CYP450 2D6 genotype from genomic deoxyribonucleic acid (DNA) obtained from whole blood samples. The INFINITI CYP450 2D6-BC Assay is a qualitative assay for use in clinical laboratories upon prescription by the attending physician.

The INFINITI CYP450 2D6-BC Assay is indicated for use as an aid to clinicians in determining therapeutic strategy for therapeutics that are metabolized by the CYP450 2D6 gene product.

The information provided from this test may supplement decision making and should only be used in conjunction with routine monitoring by a physician. Because of the variability in the knowledge of clinical utility with specific drugs that are metabolized by CYP450 2D6, clinicians should use professional judgment in the interpretation of results from this test. Results from this type of assay should not be used in predicting a patient's response to drugs for which the drug metabolizing enzyme activity of the allele, or the drug metabolic pathway, has not been clearly established.

BACKGROUND INFORMATION

Cytochrome P450 (CYP) is a major group of drug-metabolizing enzymes (DME) that consists of more than 50 isoforms. The majority of CYP activity takes place in the liver. CYP2D6 shows the largest phenotypical variability amongst the CYPs, largely due to genetic genotype accounts for normal, reduced and non-existent CYP2D6 function in subjects.

CYP2D6 is one of the most important DME genes as it metabolizes 25% to 30% of all prescribed drugs. Common drug categories metabolized by CYP2D6 include (but are not limited to): beta blockers, anti-arrhythmic, morphine derivatives, and antidepressants.

The CYP2D6 function in any particular subject may be described as one of the following:

- Poor metabolizer - these subjects have little or no CYP2D6 function.
- Intermediate metabolizers - these subjects metabolize drugs at a rate somewhere between the poor and extensive metabolizers.
- Extensive metabolizer - these subjects have normal CYP2D6 function.
- Ultra-rapid metabolizer - these subjects have multiple copies of the *CYP2D6* gene expressed, and therefore greater-than-normal CYP2D6 function.

The genetic basis for extensive and poor metabolizer variability is the *C*YP2D6 allele, located on chromosome 22. Subjects who possess certain allelic variants will show normal, decreased or no CYP2D6 function depending on the allele. Ethnicity is a factor in the occurrence of CYP2D6 variability. CYP450 2D6 genetic testing can be useful for identifying individuals who may have an adverse drug reaction or a poor response to a medication.

Table 1 Lists the CYP2D6 alleles and corresponding enzyme activity. Table 2 provides the distribution of some CYP2D6 alleles by race/ethnicity.

AutoGenomics

Table 1

***CYP2D6* allele and enzyme activity**	
Allele	CYP2D6 activity
*CYP2D6*1*	normal
*CYP2D6*2*	increased
*CYP2D6*3*	none
*CYP2D6*4*	none
*CYP2D6*5*	none
*CYP2D6*6*	none
*CYP2D6*7*	none
*CYP2D6*8*	none
*CYP2D6*9*	decreased
*CYP2D6*10*	decreased
*CYP2D6*11*	none
*CYP2D6*15*	none
*CYP2D6*17*	decreased
*CYP2D6*19*	none
*CYP2D6*20*	decreased
*CYP2D6*29*	decreased
*CYP2D6*35*	normal
*CYP2D6*36*	decreased
*CYP2D6*40*	none

Table 2

Variant	Phenotype (2D6 Function)	Allele Frequency (Percentage)		
		Caucasian	Black/African	Asian
CYP2D6*3	Poor Metabolizer	2	0	0
CYP2D6*4	Poor Metabolizer	12 - 21	2	1
CYP2D6*4XN	Poor Metabolizer	2 - 7	4	6
CYP2D6*10	Intermediate Metabolizer	1 - 2	6	51
CYP2D6*17	Intermediate Metabolizer	0	34	0

TEST PRINCIPLE/ASSAY OVERVIEW

The INFINITI CYP450 2D6-BC Assay is an *in vitro* diagnostic test for the multiplex detection of the genotypes of CYP2D6 in deoxyribonucleic acid (DNA) obtained from human blood samples.

The INFINITI CYP450 2D6-BC Assay is designed to detect and identify the following allelic variants:

Gene	Polymorphism	
CYP450 2D6	*2 (2850C>T)	*9 (2615_2617delAAG)
	*3 (2549delA)	*10 (100C>T)
	*4 (1846G>A)	*12 (124G>A)
	*5 (CYP2D6 deleted)	*17 (1023C>T)
	*6 (1707delT)	*29 (1659G>A)
	*7 (2935A>C)	*41 (2988G>A)
	*8 (1758G>T)	*XN (multiple CYP2D6)
	*14 (1758G>A)	*2A(-1584C>G)

The INFINITI CYP450 2D6-BC Assay is based on the following processes:

a) DNA extraction from human blood sample.
b) PCR amplification of purified DNA.
c) Fluorescent label incorporation using analyte specific primer extension (ASPE).
d) Hybridization of the ASPE primers to a microarray followed by washing.
e) Scanning of the microarray.
f) Signal detection and analysis.

Steps (c) through (f) are automated by the CE marked INFINITI PLUS Analyzer.

A schematic overview of the assay is shown below.



DEVICE DESCRIPTION

The INFINITI CYP450 2D6-BC Assay is an *in vitro* diagnostic device which utilizes AutoGenomics' proprietary film-based microarray technology combined with process automation, reagent management and software technology for the detection and genotyping of the CYP2D6 allelic variants in genomic deoxyribonucleic acid (DNA) obtained from whole blood samples.

The INFINITI CYP450 2D6-BC Assay is comprised of the BioFilmChip® Microarray and the Intellipac® Reagent Module.

The **Biofilm Chip Microarray** consists of a polyester film coated with proprietary multi-layer components designed for DNA analysis. The layers have been designed to provide a versatile surface to enhance test performance. The microarrays are designed to be assay specific. The INFINITI CYP450 2D6-BC Assay uses a microarray chip (P-Chip) which contains unused capture probes which could potentially be used for certain specific assays. Therefore, multiple assays can be developed using the same microarray.

The **Intellipac Reagent Module** which acts as a communication link contains up to four reservoirs that house the test reagents and has an integrated memory chip. Information on the reagent such as lot number, expiration date and number of tests is archived in the memory chip.

The INFINITI CYP450 2D6-BC Assay should be run using the AutoGenomics INFINITI PLUS Analyzer. The INFINITI PLUS Analyzer is designed for use with clinical multiplex systems intended to measure and sort multiple signals from a clinical sample. The INFINITI PLUS Analyzer is designed to measure fluorescence signals of labeled DNA target hybridized to Biofilm Chip microarrays. The Analyzer automates the CYP450 2D6-BC Assay and integrates all the discrete processes of sample (PCR amplicon) handling, reagent management, hybridization, detection, and results analysis. The assays are processed automatically and the spots are read by the built-in confocal microscope. Results are analyzed and presented as genotype calls.

The INFINITI PLUS Analyzer is CE marked.

Instructions on how to use the INFINITI PLUS Analyzer are provided in the INFINITI PLUS Analyzer Operator's Manuals.

WARNINGS AND PRECAUTIONS

Handling Requirements

- For *in vitro* diagnostic use. To be used by qualified laboratory personnel**.**
- This test is to be used only with whole blood collected in EDTA. Do not freeze/thaw blood samples. Specimens should be assayed as soon as possible.
- All patient specimens are potentially hazardous and care should be taken when handling materials of human origin. No test method can offer complete assurance that HCV, HIV or other infectious agents are absent.

  Follow the CLSI Guidelines (Molecular Diagnostics Methods for Infectious Diseases; Approved Guidelines; MM3-A).
- Upon receipt of samples, visually inspect sample condition. Specifically, look for abnormal signs that indicate that sample integrity has been compromised (e.g., evaporation, decrease in volume, precipitation, spills, discoloration, sedimentation, separation, turbidity, etc.). If you observe or suspect any sample abnormality, do not perform any test.
- Samples should be handled with extreme caution to prevent contamination, spillage, sample mix-up. Sample containers should be labeled clearly to prevent mix-up.
- Store samples at the specified conditions.
- To minimize the risk of cross contamination, sample preparation, PCR reaction set up and PCR product analysis should be performed according to approved guidelines such as CLSI (Molecular Diagnostic Methods for Genetic Diseases: Approved Guideline).
- Do not pool/mix reagents from different lots.
- Do not use a kit or reagent past its expiration date.
- Store kits and reagents according to the product label.

Laboratory Procedures

- Follow normal precautions for handling laboratory reagents.
- Follow safe laboratory procedures: do not pipette by mouth; wear protective clothing (e.g., disposable gloves and laboratory coats) and eye protection; do not eat, drink or smoke in the laboratory work areas; wash hands thoroughly after handling samples and reagents.

Waste Handling

- Dispose of unused reagents, specimens and waste according to applicable country, federal, state and local regulations.
- Safety data Sheets (SDS) are available upon request from AutoGenomics Customer Service.

Sample Preparation

- Refer to the safety instructions in the package insert provided with the DNA extraction kit used.
- The PCR product cannot be stored prior to loading it onto the microarray. Use immediately**.**

INFINITI PLUS Analyzer

- Read the Operator's Manuals before operating the instruments. Pay particular attention to "Notes".
- Follow the Caution and Safety Warning in the Operator's Manual.
- Refer to the Installation Requirements Section when installing the instrument.
- Refer to the Errors Section when errors are encountered while operating the instrument.
- Refer to the Help Section when problems are encountered.

STORAGE / STABILITY

Biofilm Chip Microarray:	24 months Refrigerated (2 to 8°C)
Intellipac Reagent:	12 months Refrigerated (2 to 8°C) **Note*:*** Remove the Intellipac from the Analyzer and store refrigerated as soon as possible. Do not use after Intellipac has been opened for four weeks.
Amplification Mix:	18 months Frozen (-30 to -15°C)

Note: Specific product expiration date is printed on the product label.

SPECIMEN COLLECTION AND STABILITY

- Peripheral blood drawn in an EDTA (purple-top) tube.
- Do not freeze / thaw blood samples. Specimens should be assayed as soon as possible.

MATERIALS PROVIDED (SUFFICIENT FOR 48 TESTS)

- Product Number 03-1430-02 INFINITI CYP450 2D6-BC BioFilmChip® Microarray Magazine
- Product Number 03-2430-02 INFINITI CYP450 2D6-BC Intellipac® Reagent Module
  24 tests per module which contains:
  - 1.1 ml ASPE Master Mix:
    - dNTPs
    - Labeled-dCTP
    - Allele Specific Primers
    - Extension Reaction Buffer
  - 2.6 ml Hybridization Buffer
    - SSC
    - Hybridization Positive Control
    - Sodium Azide Preservative 0.08%
- Product Number 03-3430-02 CYP450 2D6-BC Amplification Mix
  4 x 250µl vials of PCR reaction master mix containing:
  - dNTPs
  - PCR Primer Mix
  - $MgCl_2$
  - PCR Reaction Buffer
- Product Number 12-0330-02 : INFINITI Wash Buffer 125ml

REAGENTS REQUIRED BUT NOT PROVIDED BY AUTOGENOMICS

- DNA Extraction Kits - The INFINITI CYP450 2D6-BC Assay can detect the CYP450 2D6 allelic mutations using genomic DNA isolated from blood with sufficient purity, i.e., with the ratio of absorbance at 260 nm to absorbance at 280 nm between 1 and 4, and a concentration of 5ng/µl to 30 ng/µl DNA. Any DNA extraction method that meets this specification may be used. The user can contact AutoGenomics for further information.
- Takara Ex Taq Hot DNA Polymerase (Clontech, Catalog # RR006B for 200µl, Catalog # RR006A for 50µl).
- Titanium Taq DNA Polymerase (Clontech Catalog No: 639209)
- Shrimp Alkaline Phosphatase (SAP, USB, Catalog No: 78390)
- Exonuclease I (EXO I, USB, Catalog No: 70073X)
- Lamba Exonuclease (New England Biolabs,Catalog #M0262S for 200µL,Catalog #M0262L for 1ml).
- PCR grade water (Sigma,Catalog #W4502-1L).

EQUIPMENT

The following equipment is required but not provided with the assay reagents

- Pipettors
- Mini Centrifuge
- Pipette tips
- Microfuge tube Racks
- Thermocycler
- Vortex
- 0.2 ml thin wall tubes for PCR
- 1.5 ml micro centrifuge tubes
- 8-well Flat Strip Caps (Genesee Scientific, Catalog No. 22-623)
- AutoGenomics Product Number 11-0060-00: INFINITI Waste tray Stir Bars.
- AutoGenomics Product Number 11-0020-00: INFINITI Waste Tray Liners.
- AutoGenomics Product Number 11-0080-00: INFINITI Pipette Tips.
- AutoGenomics Product Number 10-0020-99: INFINITI PLUS Analyzer.
- AutoGenomics Product Number 11-0100-00: 48-Well Plates.
- AutoGenomics Product Number 11-0110-00: 48 Well Plate Lid.

DNA CONTROLS

It is required to run a known Positive control and a negative control. Coriell DNA samples (www.coriell.org) are suitable positive controls for many of the detected genotypes. Please contact AutoGenomics for recommendations on use of Coriell DNA.

ASSAY PROCEDURE

DNA Extraction

Follow the instructions provided with the DNA extraction kit used.

PCR Reaction

Note*:*

- Keep Taq DNA polymerase on ice.
- Completely thaw reagents on ice.
- Vortex the amplification mix tube for 2 to 5 seconds then centrifuge briefly to bring the contents
  to the bottom of the tube.
- To avoid contamination, a separate area is recommended for assembly of the PCR reaction.
  Decontaminate pipettes and all work surfaces with freshly prepared 10% bleach in deionized or distilled water.
- Filter tips and gloves must be used when handling specimens and controls.
- The PCR product cannot be stored prior to testing. Use immediately.

1. Prepare the PCR master mix for **reaction A**

Amplification mix	10.0 µl
ExTaq Polymerase (5U/µl)	0.12 µl
PCR grade water	6.88 µl
Total volume of PCR Master Mix	17.0 µl

Note: Calculate the amount of each reagent needed based on the number of reactions.

2. Gently vortex the PCR master mix then dispense 17 µl of master mix into wells of the well plate.
3. Add 3 µl of sample DNA to each well.

PCR master mix	17.0 µl
Sample DNA	3.0 µl
Total volume of amplification reaction	20.0 µl

4. Prepare the PCR master mix for **reaction B**

Amplification mix	10.0 µl
ExTaq Polymerase (5U/µl)	0.12 µl
PCR grade water	6.88 µl
Total volume of PCR Master Mix	17.0 µl

Note: Calculate the amount of each reagent needed based on the number of reactions.

5. Gently vortex the PCR master mix then dispense 17 µl of master mix into wells of the well plate.

6. Add 3 µl of sample DNA to each well.

PCR master mix	17.0 µl
Sample DNA	3.0 µl
Total volume of amplification reaction	20.0 µl

7. Place the well plate, sealed with 8-well flat strip caps, in a thermocycler and immediately commence the amplification reaction using the following program.

Step No.	Temperature	Time	No. of Cycles
1	94	2 min.	N/A
2	94 67-61.8 (-0.4°C/cycle) 68	15 sec. 15 sec. 4 min.	13x
3	94 61 68	15 sec. 15 sec. 3 min.	22x
4	68	4 min.	N/A
5	4	Hold	Hold

Note: After each cycle in step 2 the temperature is decreased by 0.4°C. When an Eppendorf Master cycler EP was used with the ramp rate set at 100%, the total cycling time was 2 hours and 40 minutes (± 5 min). If using other thermocycler models we recommend adjusting the ramp rate in order to obtain an equivalent total cycling time.

SAP and Exonuclease I Treatment

Post PCR cleanup is a critical step to ensure the remaining substrates would not carry through and interfere with the signal amplification. Prepare the enzymes mixture as a master mix. For example, if there are 19 PCR reactions, create a master mix enough for 20 reactions by pipetting 30 µl of SAP,2 µl of Exo,1.2 µl of Titanium Taq and 10µl of Lambda Exonuclease .

SAP (1U/µl)	1.50 µl
Exonuclease I (10U/µl)	0.10 µl
Titanium Taq Polymerase (50 x)	0.06 µl
Lambda Exonuclease (5U/µl)	0.50 µl
Total	2.16 µl

Dispense 2.16 µl of the enzyme mix per reaction into a clean 24WP. Dispense 10 µl from the completed PCR reaction A and 10 µl from completed PCR reaction B (of the same sample) to the 2.16 µl enzyme mix in the specified well of a 24WP. Then briefly vortex and load onto the INFINITI PLUS Analyzer.

Note: Any surplus enzyme master mix may be stored at -20°C and used again on subsequent runs. The enzyme mix is stable for six (6) months.

Sample Loading

1) Carefully remove the 8-well flat strip caps to avoid splashing.
2) Load the well plate in the appropriate orientation (with well A1 in the back left corner) into the Analyzer
   - Load the assembled 48WP with a clean 48WP lid (see instructions in the INFINITI PLUS Analyzer Operator's Manual) (Catalog # 11-0110-00, reusable).
3) Load the following: assay specific magazines, Intellipac, INFINITI Static Free Pipette tips, and buffer.
   - Follow the INFINITI PLUS Analyzer Operator's Manual for checking and replacing Buffer solution BF1.

Operation of the Analyzers

Follow the instructions in the Operator's Manuals

INFINITI PLUS Analyzer Operator's Manual (Part Number EM-34041 E)

QUALITY CONTROL

- Maintain calibration of thermocycler according to manufacturer's specifications.
- Maintain calibration of INFINITI PLUS Analyzer according to AutoGenomics 'specifications.
- Maintain calibration of pipettes according to manufacturer's specifications.

It is recommended that positive controls (heterozygous and/or homozygous samples) be included in each test run. In addition, a negative control (i.e., wild type sample) and a no template control (i.e., molecular grade water) should also be included in each test run. Coriell DNA samples (www.coriell.org) are suitable positive controls for many of the detected genotypes. Please contact AutoGenomics for recommendations on use of Coriell DNA.
Note: The thermal cycler used should be regularly maintained and calibrated with an external temperature standard, according to the laboratory's regulatory and QC requirements.

LIMITATIONS

The results obtained from the INFINITI CYP450 2D6-BC Assay should be used and interpreted only in the context of the overall clinical diagnosis. AutoGenomics is not responsible for any clinical decisions that are taken.

INTERPRETATION OF RESULTS

The INFINITI CYP450 2D6-BC Assay is designed to detect and genotype CYP450 2D6 mutations. The assay results are provided as a genotype "call", indicating which genotype was detected in the sample, i.e.,

W	=	Wild
M	=	Mutant
H	=	Heterozygous
P	=	Positive
N	=	Negative
IND	=	Indeterminate

In the analysis column an "IND" call, indicates the INFINITI call based on the data given. In case a retest is recommended. When the assay is not completed, and no genotype call is made, the assay will need to be repeated. The report displays a message which indicates the reason why no genotype call was made. When an error occurs (e.g., "low DNA"), an Error Log is generated which identifies the problem. Please refer to the Trouble Shooting section of the INFINITI PLUS operator's manual.

PERFORMANCE CHARACTERISTICS

Validation of the INFINITI CYP450 2D6-BC Assay demonstrated that the INFINITI CYP450 2D6-BC Assay is equivalent to the CE-marked INFINITI CYP450 2D6I Assay when used on blood specimens

Limit of Detection (LoD)

A limit of detection study was conducted using Coriell DNA samples. The starting concentration and the absorbance ratios were measured using the Nanodrop for each Coriell DNA sample to establish the purity of the DNA sample. The Coriell DNA samples were titrated from the starting concentration which ranged from 482-240ng/µl to a concentration range of 0.66-0.33 ng DNA /µl. The dilutions were tested using the INFINITI CYP2D6-BC Assay. Negative samples were used as controls. Results from both instruments agreed with the expected genotype calls 100%. RFU signals did not vary significantly throughout the concentration ranges tested.

The LOD study demonstrated that the INFINITI CYP450 2D6-BC Assay can detect the target mutations at the recommended DNA input concentration of 3-30ng DNA/µl. The assay requires 3 µl of the DNA sample for 9-90 ng/µl DNA input per test.

Analytical Specificity-Method Comparison

The INFINITI CYP450 2D6-BC Assay was compared to the CE-marked INFINITI CYP450 2D6I Assay as the comparator method. The comparison study involved twenty (20) qualified whole blood patient samples. Patient samples were de-identified to protect patient's identity. Coriell samples and negative samples were used as controls. Samples were run in duplicate.

The results of the INFINITI CYP450 2D6-BC Assay were compared to the results of the INFINITI CYP450 2D6I Assay. Discordance between the CYP450 2D6-BC Assay results and the expected results was resolved by repeating the CYP450 2D6-BC testing. Only one repeat (in duplicate) was allowed. Final test results demonstrated 98% concordance between the

CYP450 2D6-BC Assay results and the expected genotype calls. There was one IND/ No call test result.

The following table provides a listing of the samples tested and the final test results.

Sample ID	Type	Genotype	% Agreement
1	Blood	WT	50%[see note below]
2	Blood	*3H	100%
3	Blood	*2H,*4H, 100T H, -1584H	100%
4	Blood	*10 M	100%
5	Blood	*2M, -1584H,*41H	100%
6	Blood	*10H	100%
7	Blood	WT	100%
8	Blood	*2H,*10H,-1584H	100%
9	Blood	*4H,*10H	100%
10	Blood	*2H,*4H,*10H, -1584H	100%
11	Blood	*2H,*41H	100%
12	Blood	*2M,*17H,-1584H	100%
13	Blood	*2H,*41H	100%
14	Blood	*4H, *10H	100%
15	Blood	*9H	100%
16	Blood	*2M,-1584H,*41H	100%
17	Blood	*10H	100%
18	Blood	*2M,-1584H,*41H	100%
19	Blood	*2H,-1584H	100%
20	Blood	WT	100%
21	Coriell	*2H,*4H,*10H,*41H,*XN-P	100%
22	Coriell	*9M,*5P	100%
23	Coriell	*2M,*29M,*5P	100%
24	Water	NTCE	100%
25	TE Buffer	NTCE	100%

Note: one of two tests gave an IND/No call result

Reproducibility Study

The reproducibility of the INFINITI CYP450 2D6-BC Assay was assessed by evaluating the INFINITI CYP450 2D6-BC test results using five lots of reagents, five instruments and five operators. Nine (9) Coriell DNA controls were used for a total of 80 tests. Of the 80 test, 63(88.8%) were correct calls, eight (8) (7.4%) were no calls and three (3) (3.7%) incorrect calls. Repeat testing was not performed during the reproducibility study. The following provides a summary of the reproducibility study.

Coriell ID	Genotype	# Tests	% correct calls	% no calls	% incorrect calls
15269	M*2,-1584,*XN	9	8	1	
17121	H*2,*4,*10,*17	9	8		1
17138	M*2,*29,*5	9	8	1	
17164	*2H,*4H,*10H,*41H, *XN-P	9	9		
17208	M*2,H*41,-1584	9	9		
17280	H*2,*3,-1584	9	7	2	
17281	M*9,*5	9	7	2	
17300	H*6	9	9		
18552	H*2,*14,-1584	9	7		2
Total		**80**	**88.8%**	**7.4%%**	**3.7%**

Potential Interference from Drugs/Chemicals

Both INFINITI CYP450 2D6I Assay and INFINITI CYP450 2D6-BC Assay use whole blood as specimen. Therefore the interference study for INFINITI CYP450 2D6I Assay applies to INFINITI CYP450 2D6-BC Assay. The interference study demonstrated that INFINITI CYP450 2D6-BCAassay performance will not be affected by the addition of the following substances.

Substance Added	Concentration
Bilirubin, Conjugated	60 mg/dl
Bilirubin, Unconjugated	60 mg/dl
Triglycerides	3000 mg/dl
Human albumin	6 g/dl